Regulus Therapeutics Inc. (NASDAQ:RGLS) Trend Analysis released that optimistic new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients. Regulus Therapeutics Inc. (NASDAQ:RGLS) stock price closed at $16.85 with the total traded volume of 1.08 Million shares. Its price to sales ratio ended at 92.01. Its market capitalization is 819.0 Million. The stock owned by the Financial Institutions was 29.60% while by insiders was 12.30%.Amicus Therapeutics, Inc. (NASDAQ:FOLD) Trend Analysis released that additional optimistic data on important secondary endpoints from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl for Fabry disease. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has the market capitalization of 531.5 Million. Shares of firm climbed 17.75% to close at $6.70 with the total traded volume of 5.92 Million. The firm has current ratio of 6.30 for the most recent quarter.Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) Trend Analysis released that its results from a 48-week Open Label Extension safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease patients with elevated serum phosphorus levels, or hyperphosphatemia. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) begun last trade with a price of $15.51 and throughout the trading session climbed at a high of $15.6902. The day-trade ended with -0.20% to $15.18. The stock is going forward to its 52 week low with 31.66% and lagging behind from its 52 week high price with -17.86%. KERX last month stock price volatility remained 4.83%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
